Results 211 to 220 of about 2,052,688 (283)

Biomaterial Platforms for Spatiotemporal Control of mRNA Delivery in Tissue Engineering and Regenerative Medicine: Design Rules, Therapeutic Applications, and Translational Roadmap

Small, EarlyView.
Biomaterial platforms can control where and when mRNA‐encoded proteins are expressed to support tissue repair. This Review proposes a cargo–target–timing framework linking therapeutic function, target tissues and cells, and expression profiles with carrier and scaffold design.
Huachun Pan, Shumin Yang, Katarina Holubova, Huifang Yin, Hongbo Chen, Xintian Zheng, Xiangan Han, Jinqiu Zhang, Xueping Li, Hui Zhang, Xiaojun Cai, Václav Slovák, Lihong Zhang, Quan Mo, Quazi T. H. Shubhra   +14 more
wiley   +1 more source

Designed Peptide Coacervates for Extracellular Antibody Targeting

Small, EarlyView.
Peptide‐based coacervates formed by liquid‐liquid phase separation provide a membraneless platform for therapeutic antibody delivery. Using Rituximab as a model, these coacervates enable efficient encapsulation, enhanced cell interactions, and provide partial protection from enzymatic proteolysis while maintaining low cytotoxicity.
Nofar Berman, Omer Grotto, Limor Nahary, Itai Benhar, Ayala Lampel   +4 more
wiley   +1 more source

Engineering chimeric antigen receptor CD4 T cells for Alzheimer's disease. [PDF]

Proc Natl Acad Sci U S A
Boskovic P, Shalita R, Gao W, Vernon H, Deng YL, Colonna M, Majzner RG, Amit I, Kipnis J.   +8 more
europepmc   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Development and characterization of chimeric antigen receptor macrophages for amyloid clearance. [PDF]

Front Immunol
Balachandran M, Foster JS, Hancock TJ, Martin EB, Jackson JW, Angell N, Wall JS.   +6 more
europepmc   +1 more source

Advances in research on layered double hydroxides for biomedical applications

Smart Molecules, EarlyView.
Layered double hydroxides (LDHs) are pH‐responsive nanomaterials with broad biomedical applications. This review summarizes LDH synthesis methods and compares their advantages. It highlights LDHs' progress in cancer therapy, including chemo‐photothermal, chemo‐immunotherapy, and photodynamic‐immunotherapy combinations and their potential in bone repair.
Xinhui Yang, Zhiping Zhang, Zhao Wang, Hao Zhang, Yen Leng Pak, Yingying Jing, Yurong Guo, Fang Li, Xiao Wang, Quanxiang Han, Lei Yu, Xuejiao Li, Xing Gao, Jibin Song   +13 more
wiley   +1 more source

Dual B -Cell Maturation Antigen/CD19 Chimeric Antigen Receptor- T Therapy for AL Amyloidosis : Targeting the Clone, Saving the Kidney. [PDF]

J Am Soc Nephrol
Sobczak K, Leick MB.
europepmc   +1 more source

Dynamic risk stratification using early CAR‐T expansion in R/R LBCL treated with axicabtagene ciloleucel

British Journal of Haematology, EarlyView.
Higher chimeric antigen receptor‐T expansion at day 7 is associated with improved progression‐free survival but also increased toxicity in axi‐cel treated patients with R/R large B‐cell lymphoma, independent of other baseline patient and disease characteristics.
Brydon Panozzo, Samuel Robinson, Adrian G. Minson, Jian Li, Kylie Baldwin, Hamish W. Scott, Jane Oliaro, Aaron J. N. Wong, Samantha van der Linde, Nicole L. O'Leary, Philip A. Thompson, John F. Seymour, Mary Ann Anderson, Constantine S. Tam, Simon J. Harrison, Michael J. Dickinson, David A. Westerman, Mark R. Dowling   +17 more
wiley   +1 more source

Multi-antigen chimeric antigen receptor-T cell therapy for relapsed/refractory B cell lymphomas. [PDF]

Front Immunol
Pandey T, Samat D, Dahiya S, Patel SA.
europepmc   +1 more source